Concurrent use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) in patients (pts) with advanced urothelial carcinoma (UC) receiving enfortumab vedotin (EV) plus pembrolizumab (P) therapy.

Steven N. Seyedin, Nataliya Mar, Cindy Jiang et al.|Journal of Clinical Oncology|2026

Cited by 0